{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-25-000863","form_type":"8-K","ticker":"ZEOX","cik":"0001557376","company_name":"Zeo ScientifiX, Inc.","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.985118+00:00","generated_at":"2026-05-26T23:20:58.717217+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"medium","headline":"Zeo ScientifiX update: Phase I Zofin trial complete, PPX revenue up $474K, partnerships expanded","bullets":["Completed Phase I safety trials for flagship Zofin; plans to amend INDs for Phase II targeting Osteoarthrosis and COPD.","PPX autologous product revenue increased by approximately $474,000 in FY2024 compared to prior fiscal year.","Issued patents for amniotic fluid processing techniques and PPX blood-derived exosome pain treatment method in past year.","Strategic partnership with Physicians Group LLC, operating 75 clinics and 750 clinicians, for collaborative research and clinical trials.","Launched ZEO HAIR GROW topical product with Exotropin; aims at hair loss market affecting 35M men and 31M women in US."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-25-000863","json":"https://secwatch.observer/filing/0001829126-25-000863.json","markdown":"https://secwatch.observer/filing/0001829126-25-000863.md","text":"https://secwatch.observer/filing/0001829126-25-000863.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557376/000182912625000863/0001829126-25-000863-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557376/000182912625000863/zeoscientifix_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:20:58.717217+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}